The laboratory investigation, management, and infection prevention and control of Candida auris: a narrative review to inform the 2024 national guidance update in England
Authors:
- Christopher R. JonesCJChristopher R. Jones
- Claire NeillCNClaire Neill
- Andrew M. BormanABAndrew M. Borman
- Emma L. BuddEBEmma L. Budd
- Martina CumminsMCMartina Cummins
- Carole FryCFCarole Fry
- Rebecca L. GuyRGRebecca L. Guy
- Katie JefferyKJKatie Jeffery
- Elizabeth M. JohnsonEJElizabeth M. Johnson
- Rohini ManuelRMRohini Manuel
- Mariyam MirfendereskyMMMariyam Mirfenderesky
- Ginny MooreGMGinny Moore
Open Access
- 21 May 2024
- journal article
- review article
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 73 (5) , 001820
Abstract
The emergent fungal pathogen Candida auris is increasingly recognised as an important cause of healthcare-associated infections globally. It is highly transmissible, adaptable, and persistent, resulting in an organism with significant outbreak potential that risks devastating consequences. Progress in the ability to identify C. auris in clinical specimens is encouraging, but laboratory diagnostic capacity and surveillance systems are lacking in many countries. Intrinsic resistance to commonly used antifungals, combined with the ability to rapidly acquire resistance to therapy, substantially restricts treatment options and novel agents are desperately needed. Despite this, outbreaks can be interrupted, and mortality avoided or minimised, through the application of rigorous infection prevention and control measures with an increasing evidence base. This review provides an update on epidemiology, the impact of the COVID-19 pandemic, risk factors, identification and typing, resistance profiles, treatment, detection of colonisation, and infection prevention and control measures for C. auris. This review has informed a planned 2024 update to the United Kingdom Health Security Agency (UKHSA) guidance on the laboratory investigation, management, and infection prevention and control of Candida auris. A multidisciplinary response is needed to control C. auris transmission in a healthcare setting and should emphasise outbreak preparedness and response, rapid contact tracing and isolation or cohorting of patients and staff, strict hand hygiene and other infection prevention and control measures, dedicated or single-use equipment, appropriate disinfection, and effective communication concerning patient transfers and discharge.Keywords
This publication has 156 references indexed in Scilit:
- The use of readily available laboratory tests for the identification of the emerging yeast Candida auris in MexicoArchives of Microbiology, 2022
- MycoSNP: A Portable Workflow for Performing Whole-Genome Sequencing Analysis of Candida auris2022
- Candida auris Candidemia in Critically Ill, Colonized Patients: Cumulative Incidence and Risk FactorsInfectious Diseases and Therapy, 2022
- Public health issues with Candida auris in COVID‐19 patientsWorld Medical & Health Policy, 2021
- Ominous combination: COVID‐19 disease and Candida auris fungemia—Case report and review of the literatureClinical Case Reports, 2021
- Candida auris: Diagnostic Challenges and Emerging Opportunities for the Clinical Microbiology LaboratoryCurrent Fungal Infection Reports, 2021
- Molecular Diagnosis of Yeast InfectionsCurrent Fungal Infection Reports, 2021
- A decade after the emergence of Candida auris: what do we know?European Journal of Clinical Microbiology & Infectious Diseases, 2020
- Incidence, characteristics and outcome of ICU-acquired candidemia in IndiaIntensive Care Medicine, 2014
- Multidrug-resistant endemic clonal strain of Candida auris in IndiaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2013